Medical Education Division
 Our Products
On-Line Store
Google
 
Web www.brooksidepress.org

Operational Medicine 2001
Norethindrone and Ethinyl Estradiol (Tri-Norinyl)

Home  ·  Military Medicine  ·  Sick Call  ·  Basic Exams  ·  Medical Procedures  ·  Lab and X-ray  ·  The Pharmacy  ·  The Library  ·  Equipment  ·  Patient Transport  ·  Medical Force Protection  ·  Operational Safety  ·  Operational Settings  ·  Special Operations  ·  Humanitarian Missions  ·  Instructions/Orders  ·  Other Agencies  ·  Video Gallery  ·  Phone Consultation  ·  Forms  ·  Web Links  ·  Acknowledgements  ·  Help  ·  Feedback
 
 

Category:

  • Hormone

Description:

  • Triphasic oral contraceptive

    • Phase 1: norethindrone 0.5mg, ethinyl estradiol 35mcg

    • Phase 2: norethindrone 1mg, ethinyl estradiol 35mcg

    • Phase 3: norethindrone 0.5mg, ethinyl estradiol 35mcg

Indications:

  • Contraceptive

Contraindications:

  • Pregnancy

  • Undiagnosed abnormal vaginal bleeding

  • Known or suspected benign or malignant liver tumors while on oral contraceptive use

  • Breast carcinoma or estrogen-dependent neoplasia

  • Current or history of thromboembolic disorders, cerebral vascular or cardiovascular disease.

Precautions:

  • Pregnancy category X

  • Take as directed at intervals not exceeding 24 hours.  Efficiency is dependent upon strict compliance.

  • OCPs are 99.9% effective after the 1st month, if taken according to the prescribed schedule. 

  • During the first month, effectiveness depends on how many OCPs have been taken, but overall are about 95% effective, comparable to condoms or a diaphragm.

  • Breakthrough bleeding (“spotting”) may occur during initiation of therapy.

  • Instructions for missed doses:

    • One missed dose: Take as soon as possible or two tablets the next day and continue

    • Two missed doses: Take two tablets daily for two days, then continue normal schedule

    • Three missed doses: Discontinue therapy and begin new packet 7 days following last dose

  • May cause mental depression, fluid retention and depressed folate levels

  • Twenty-eight day packs contain seven days of inert ingredients to maintain regimen

Adverse Reactions (Side Effects):

  • Abdominal cramping, anorexia, nausea, vomiting

  • Acne (Usually makes it better)

  • Breast tenderness

  • Edema, weight gain

  • Unusual tiredness or weakness

  • Cardiovascular disorders (hypertension)

  • Thromboembolic disorders

Dosage:

  • Administered orally

  • One tablet daily for 21 or 28 days beginning on the:

    • Fifth day of the cycle, or

    • First Sunday after the beginning of flow

For more information on Oral Contraceptive Pills, read:

  •  

    •  

    Approved for public release; Distribution is unlimited.

    The listing of any non-Federal product in this CD is not an endorsement of the product itself, but simply an acknowledgement of the source. 

    Operational Medicine 2001

    Health Care in Military Settings

    Bureau of Medicine and Surgery
    Department of the Navy
    2300 E Street NW
    Washington, D.C
    20372-5300

    Operational Medicine
     Health Care in Military Settings
    CAPT Michael John Hughey, MC, USNR
    NAVMED P-5139
      January 1, 2001

    		 United States Special Operations Command
    7701 Tampa Point Blvd.
    MacDill AFB, Florida
    33621-5323

    *This web version is provided by The Brookside Associates Medical Education Division.  It contains original contents from the official US Navy NAVMED P-5139, but has been reformatted for web access and includes advertising and links that were not present in the original version. This web version has not been approved by the Department of the Navy or the Department of Defense. The presence of any advertising on these pages does not constitute an endorsement of that product or service by either the US Department of Defense or the Brookside Associates. The Brookside Associates is a private organization, not affiliated with the United States Department of Defense.

    Contact Us  ·  ·  Other Brookside Products